FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945441427> ?p ?o ?g. }

• W2945441427 endingPage "153" @default.
• W2945441427 startingPage "145" @default.
• W2945441427 abstract "Abstract Background The high cost and insufficient supply of human papillomavirus (HPV) vaccines have slowed the pace of controlling cervical cancer. A phase III clinical trial was conducted to evaluate the efficacy, safety, and immunogenicity of a novel Escherichia coli-produced bivalent HPV-16/18 vaccine. Methods A multicenter, randomized, double-blind trial started on November 22, 2012 in China. In total, 7372 eligible women aged 18–45 years were age-stratified and randomly assigned to receive three doses of the test or control (hepatitis E) vaccine at months 0, 1, and 6. Co-primary endpoints included high-grade genital lesions and persistent infection (over 6 months) associated with HPV-16/18. The primary analysis was performed on a per-protocol susceptible population of individuals who were negative for relevant HPV type-specific neutralizing antibodies (at day 0) and DNA (at day 0 through month 7) and who received three doses of the vaccine. This report presents data from a prespecified interim analysis used for regulatory submission. Results In the per-protocol cohort, the efficacies against high-grade genital lesions and persistent infection were 100.0% (95% confidence interval = 55.6% to 100.0%, 0 of 3306 in the vaccine group vs 10 of 3296 in the control group) and 97.8% (95% confidence interval = 87.1% to 99.9%, 1 of 3240 vs 45 of 3246), respectively. The side effects were mild. No vaccine-related serious adverse events were noted. Robust antibody responses for both types were induced and persisted for at least 42 months. Conclusions The E coli-produced HPV-16/18 vaccine is well tolerated and highly efficacious against HPV-16/18–associated high-grade genital lesions and persistent infection in women." @default.
• W2945441427 created "2019-05-29" @default.
• W2945441427 creator A5000594791 @default.
• W2945441427 creator A5001724194 @default.
• W2945441427 creator A5003061709 @default.
• W2945441427 creator A5005247111 @default.
• W2945441427 creator A5005464512 @default.
• W2945441427 creator A5008201587 @default.
• W2945441427 creator A5009744576 @default.
• W2945441427 creator A5009884211 @default.
• W2945441427 creator A5010701166 @default.
• W2945441427 creator A5010898734 @default.
• W2945441427 creator A5011480240 @default.
• W2945441427 creator A5015518758 @default.
• W2945441427 creator A5017489902 @default.
• W2945441427 creator A5017960444 @default.
• W2945441427 creator A5021634528 @default.
• W2945441427 creator A5023533442 @default.
• W2945441427 creator A5030547637 @default.
• W2945441427 creator A5033560825 @default.
• W2945441427 creator A5035886812 @default.
• W2945441427 creator A5037600539 @default.
• W2945441427 creator A5042167444 @default.
• W2945441427 creator A5042772858 @default.
• W2945441427 creator A5043859457 @default.
• W2945441427 creator A5046143675 @default.
• W2945441427 creator A5047497897 @default.
• W2945441427 creator A5053780153 @default.
• W2945441427 creator A5057760744 @default.
• W2945441427 creator A5060310839 @default.
• W2945441427 creator A5064591982 @default.
• W2945441427 creator A5064685242 @default.
• W2945441427 creator A5064711465 @default.
• W2945441427 creator A5069951259 @default.
• W2945441427 creator A5070139617 @default.
• W2945441427 creator A5070168366 @default.
• W2945441427 creator A5071672663 @default.
• W2945441427 creator A5074647962 @default.
• W2945441427 creator A5077645027 @default.
• W2945441427 creator A5078128438 @default.
• W2945441427 creator A5078732636 @default.
• W2945441427 creator A5082077174 @default.
• W2945441427 creator A5082267036 @default.
• W2945441427 creator A5082815416 @default.
• W2945441427 creator A5084261477 @default.
• W2945441427 creator A5091127554 @default.
• W2945441427 creator A5091738450 @default.
• W2945441427 date "2019-05-14" @default.
• W2945441427 modified "2023-10-16" @default.
• W2945441427 title "Efficacy, Safety, and Immunogenicity of an Escherichia coli-Produced Bivalent Human Papillomavirus Vaccine: An Interim Analysis of a Randomized Clinical Trial" @default.
• W2945441427 cites W1963888311 @default.
• W2945441427 cites W1981725818 @default.
• W2945441427 cites W1984688277 @default.
• W2945441427 cites W2001429203 @default.
• W2945441427 cites W2007245430 @default.
• W2945441427 cites W2024662155 @default.
• W2945441427 cites W2041307935 @default.
• W2945441427 cites W2043746949 @default.
• W2945441427 cites W2059707463 @default.
• W2945441427 cites W2103834380 @default.
• W2945441427 cites W2113311378 @default.
• W2945441427 cites W2121189112 @default.
• W2945441427 cites W2127043059 @default.
• W2945441427 cites W2131255017 @default.
• W2945441427 cites W2133765716 @default.
• W2945441427 cites W2136175711 @default.
• W2945441427 cites W2139975677 @default.
• W2945441427 cites W2141921059 @default.
• W2945441427 cites W2142200682 @default.
• W2945441427 cites W2159831861 @default.
• W2945441427 cites W2161009787 @default.
• W2945441427 cites W2209279645 @default.
• W2945441427 cites W2339853485 @default.
• W2945441427 cites W2404982942 @default.
• W2945441427 cites W2527528289 @default.
• W2945441427 cites W2559124996 @default.
• W2945441427 cites W2586227482 @default.
• W2945441427 cites W2605365014 @default.
• W2945441427 cites W2738852122 @default.
• W2945441427 cites W316269977 @default.
• W2945441427 cites W4299149158 @default.
• W2945441427 cites W4301044136 @default.
• W2945441427 cites W2985532529 @default.
• W2945441427 doi "https://doi.org/10.1093/jnci/djz074" @default.
• W2945441427 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7019098" @default.
• W2945441427 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31086947" @default.
• W2945441427 hasPublicationYear "2019" @default.
• W2945441427 type Work @default.
• W2945441427 sameAs 2945441427 @default.
• W2945441427 citedByCount "92" @default.
• W2945441427 countsByYear W29454414272019 @default.
• W2945441427 countsByYear W29454414272020 @default.
• W2945441427 countsByYear W29454414272021 @default.
• W2945441427 countsByYear W29454414272022 @default.
• W2945441427 countsByYear W29454414272023 @default.
• W2945441427 crossrefType "journal-article" @default.
• W2945441427 hasAuthorship W2945441427A5000594791 @default.
• W2945441427 hasAuthorship W2945441427A5001724194 @default.

• next